Human interleukin-2 Completed Phase 3 Trials for Metastatic Renal Cell Carcinoma ( mRCC) Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00291369Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis